Whalesbook
Valuation Gap Emerges in Booming Sector
Private equity firm Kedaara Capital is reportedly preparing to sell its stake in Indian nutraceutical company Universal NutriScience (UNS). The firm is aiming for a valuation of around ₹3,000 crore. However, the sale faces opposition from prospective buyers who consider Kedaara's target of roughly 30 times projected FY26 EBITDA to be too high. These potential acquirers suggest a more realistic valuation would be between 20 and 25 times EBITDA. Kedaara Capital manages approximately $5.5 billion in assets and is targeting this multiple on projected FY26 EBITDA of around ₹100 crore, with revenues estimated at ₹350-400 crore.
The Indian nutraceutical market itself presents a strong growth narrative, currently valued at approximately $8 billion and projected to expand at an 11% compound annual growth rate (CAGR) through 2027. This growth is fueled by rising disposable incomes, increased health consciousness among consumers, especially post-pandemic, and greater product accessibility via digital channels. Globally, the nutraceutical market exceeds $520 billion and is growing at an 8-9% CAGR. Sector investments in India surged 2.5 times between 2020 and 2023 compared to the preceding period.
Universal NutriScience was established in 2021 when it acquired 16 nutraceutical brands from Sanofi India for ₹587 crore, including well-known names like Seacod. The company reported FY25 revenue of ₹230 crore and EBITDA of ₹61 crore. In the broader Indian healthcare sector, M&A activity has remained robust, with deal values exceeding ₹10,000 crore in the second quarter of FY26, driven by investor interest in hospitals, diagnostics, and specialty care. Leading listed healthcare players often command enterprise value (EV) to EBITDA multiples ranging from the mid-teens to over 30x. However, buyers may feel UNS's current financials do not fully support Kedaara's target multiple, despite general market premiums.
Deal Faces Hurdles Amid Competition and Integration Needs
The significant valuation gap presents a substantial risk to the Universal NutriScience sale. If Kedaara Capital remains firm on its valuation, the deal could collapse, potentially leading to a protracted sale process or forcing Kedaara to re-evaluate its exit strategy.
UNS operates in a competitive market that includes global giants such as Herbalife, Amway, Nestlé, and Pfizer, alongside specialized players like ChromaDex and Ritual. Maintaining market share and growth momentum against these established companies requires continuous innovation and substantial marketing investment. Furthermore, as UNS was formed in 2021 through the acquisition of Sanofi brands, the integration of these brands and realization of synergies remain critical ongoing tasks, which can introduce execution risks. While Kedaara Capital is known for operational improvements, the proposed premium valuation may be pricing in future growth that is not yet fully demonstrated or guaranteed, potentially exposing the firm if market conditions change or competitive pressures intensify.
Sale Outcome Could Signal Market Trends
The outcome of Kedaara's potential sale of Universal NutriScience will serve as a key indicator for M&A appetite and valuation expectations within India's attractive nutraceutical and broader healthcare sectors. While investor sentiment for the sector remains positive, the current valuation standoff suggests that buyers are exercising greater scrutiny and discipline. The market will be observing whether Kedaara can bridge the valuation gap or if the sale process stalls, which could influence future deal-making dynamics as valuation multiples in the Indian market continue to evolve.